BACKGROUND: Zoster vaccine is a single dose live, attenuated vaccine (ZVL) indicated for individuals ≥50 years-old for the prevention of herpes zoster (HZ). Safety data from clinical trials and post-licensure studies provided reassurance that ZVL is generally safe and well tolerated. The objective of this review was to provide worldwide post-marketing safety information following 10 years of use and >34 million doses distributed. METHODS: All post-marketing adverse experience (AE) reports received worldwide between 02-May-2006 and 01-May-2016 from healthcare professionals following vaccination with ZVL and submitted to the MSD AE global safety database, were analyzed. RESULTS: A total of 23,556 AE reports, 93% non-serious, were reported. Local injection site reactions (ISRs), with a median time-to-onset of 2 days, were the most frequently reported AEs followed by HZ. The majority of HZ reports were reported within 2 weeks of vaccination and considered, based on time-to-onset, pathogenesis of HZ, and data from clinical trials, to be caused by wild-type varicella-zoster virus (VZV). HZ confirmed by PCR analysis to be VZV Oka/Merck vaccine-strain was identified in an immunocompetent individual 8 months postvaccination and in 4 immunocompromised individuals. Disseminated HZ was reported very rarely (<1%) with 38% occurring in immunocompromised individuals. All reports of disseminated HZ confirmed by PCR as VZV Oka/Merck vaccine-strain were in individuals with immunosuppressive conditions and/or therapy at the time of vaccination. CONCLUSIONS: The safety profile of ZVL, following 10 years of post-marketing use, was favorable and consistent with that observed in clinical trials and post-licensure studies.
BACKGROUND: Zoster vaccine is a single dose live, attenuated vaccine (ZVL) indicated for individuals ≥50 years-old for the prevention of herpes zoster (HZ). Safety data from clinical trials and post-licensure studies provided reassurance that ZVL is generally safe and well tolerated. The objective of this review was to provide worldwide post-marketing safety information following 10 years of use and >34 million doses distributed. METHODS: All post-marketing adverse experience (AE) reports received worldwide between 02-May-2006 and 01-May-2016 from healthcare professionals following vaccination with ZVL and submitted to the MSD AE global safety database, were analyzed. RESULTS: A total of 23,556 AE reports, 93% non-serious, were reported. Local injection site reactions (ISRs), with a median time-to-onset of 2 days, were the most frequently reported AEs followed by HZ. The majority of HZ reports were reported within 2 weeks of vaccination and considered, based on time-to-onset, pathogenesis of HZ, and data from clinical trials, to be caused by wild-type varicella-zoster virus (VZV). HZ confirmed by PCR analysis to be VZV Oka/Merck vaccine-strain was identified in an immunocompetent individual 8 months postvaccination and in 4 immunocompromised individuals. Disseminated HZ was reported very rarely (<1%) with 38% occurring in immunocompromised individuals. All reports of disseminated HZ confirmed by PCR as VZV Oka/Merck vaccine-strain were in individuals with immunosuppressive conditions and/or therapy at the time of vaccination. CONCLUSIONS: The safety profile of ZVL, following 10 years of post-marketing use, was favorable and consistent with that observed in clinical trials and post-licensure studies.
Authors: Neal A Halsey; Kathryn M Edwards; Cornelia L Dekker; Nicola P Klein; Roger Baxter; Philip Larussa; Colin Marchant; Barbara Slade; Claudia Vellozzi Journal: Vaccine Date: 2012-04-14 Impact factor: 3.641
Authors: N Macaladad; T Marcano; M Guzman; J Moya; F Jurado; M Thompson; C Meechan; D Li; K Schlienger; I Chan; J Sadoff; F Schödel; J L Silber Journal: Vaccine Date: 2006-11-27 Impact factor: 3.641
Authors: Michael S Simberkoff; Robert D Arbeit; Gary R Johnson; Michael N Oxman; Kathy D Boardman; Heather M Williams; Myron J Levin; Kenneth E Schmader; Lawrence D Gelb; Susan Keay; Kathleen Neuzil; Richard N Greenberg; Marie R Griffin; Larry E Davis; Vicki A Morrison; Paula W Annunziato Journal: Ann Intern Med Date: 2010-05-04 Impact factor: 25.391
Authors: Kenneth E Schmader; Myron J Levin; John W Gnann; Shelly A McNeil; Timo Vesikari; Robert F Betts; Susan Keay; Jon E Stek; Nickoya D Bundick; Shu-Chih Su; Yanli Zhao; Xiaoming Li; Ivan S F Chan; Paula W Annunziato; Janie Parrino Journal: Clin Infect Dis Date: 2012-01-30 Impact factor: 9.079
Authors: C Raina MacIntyre; Tony Egerton; Malcolm McCaughey; Janie Parrino; Bernadette V Campbell; Shu-Chih Su; Marco F Pagnoni; Jon E Stek; Jin Xu; Paula W Annunziato; Ivan S F Chan; Jeffrey L Silber Journal: Hum Vaccin Date: 2010-11-01
Authors: Mona Marin; Barbara P Yawn; Craig M Hales; Peter C Wollan; Stephanie R Bialek; John Zhang; Marge J Kurland; Rafael Harpaz Journal: Hum Vaccin Immunother Date: 2015 Impact factor: 3.452
Authors: Boris Kerzner; Alexander V Murray; Eric Cheng; Rudy Ifle; Peter R Harvey; Mark Tomlinson; Julie L Barben; Kimberly Rarrick; Jon E Stek; Mi-Ok Chung; Florian P Schödel; William W B Wang; Jin Xu; Ivan S F Chan; Jeffrey L Silber; Katia Schlienger Journal: J Am Geriatr Soc Date: 2007-10 Impact factor: 5.562
Authors: Vicki A Morrison; Michael N Oxman; Myron J Levin; Kenneth E Schmader; John C Guatelli; Robert F Betts; Larry D Gelb; Constance T Pachucki; Susan K Keay; Barbara Menzies; Marie R Griffin; Carol A Kauffman; Adriana R Marques; John F Toney; Michael S Simberkoff; Richard Serrao; Robert D Arbeit; John W Gnann; Richard N Greenberg; Mark Holodniy; Wendy A Keitel; Shingshing S Yeh; Larry E Davis; George E Crawford; Kathy M Neuzil; Gary R Johnson; Jane H Zhang; Rith Harbecke; Ivan S F Chan; Paul M Keller; Heather M Williams; Kathy D Boardman; Jeffrey L Silber; Paula W Annunziato Journal: J Infect Dis Date: 2013-04-30 Impact factor: 5.226
Authors: Elaine R Miller; Paige Lewis; Tom T Shimabukuro; John Su; Pedro Moro; Emily Jane Woo; Christopher Jankosky; Maria Cano Journal: Hum Vaccin Immunother Date: 2018-05-18 Impact factor: 3.452
Authors: Laura P Hurley; Mandy A Allison; Kathleen L Dooling; Sean T O'Leary; Lori A Crane; Michaela Brtnikova; Brenda L Beaty; Jessica A Allen; Angela Guo; Megan C Lindley; Allison Kempe Journal: Vaccine Date: 2018-10-26 Impact factor: 3.641
Authors: Cosby A Stone; Christine R F Rukasin; Thomas M Beachkofsky; Elizabeth J Phillips Journal: Br J Clin Pharmacol Date: 2019-11-05 Impact factor: 4.335
Authors: Adriana Bastidas; Javier de la Serna; Mohamed El Idrissi; Lidia Oostvogels; Philippe Quittet; Javier López-Jiménez; Filiz Vural; David Pohlreich; Tsila Zuckerman; Nicolas C Issa; Gianluca Gaidano; Je-Jung Lee; Sunil Abhyankar; Carlos Solano; Jaime Perez de Oteyza; Michael J Satlin; Stefan Schwartz; Magda Campins; Alberto Rocci; Carlos Vallejo Llamas; Dong-Gun Lee; Sen Mui Tan; Anna M Johnston; Andrew Grigg; Michael J Boeckh; Laura Campora; Marta Lopez-Fauqued; Thomas C Heineman; Edward A Stadtmauer; Keith M Sullivan Journal: JAMA Date: 2019-07-09 Impact factor: 56.272
Authors: Zoran Popmihajlov; Lei Pang; Elizabeth Brown; Amita Joshi; Shu-Chih Su; Susan S Kaplan; English D Willis Journal: Hum Vaccin Immunother Date: 2018-09-05 Impact factor: 3.452